MOTOLIMOD
Motolimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target toll-like receptor 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 4 | 1 | — | — | — | 5 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 1 | — | — | — | 4 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 1 | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | — | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | 2 | — | — | — | 3 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
| Peritoneal neoplasms | D010534 | — | — | — | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | — | — | — | — | 3 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
| Oropharyngeal neoplasms | D009959 | — | — | 1 | — | — | — | — | 1 |
| Unknown primary neoplasms | D009382 | — | — | 1 | — | — | — | — | 1 |
| Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | 1 | — | — | — | — | 1 |
| Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | 1 | — | — | — | — | 1 |
| Verrucous carcinoma | D018289 | — | — | 1 | — | — | — | — | 1 |
| Paranasal sinus neoplasms | D010255 | — | — | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MOTOLIMOD |
| INN | motolimod |
| Description | Motolimod (VTX-2337) is a drug which acts as a potent and selective agonist of toll-like receptor 8 (TLR8), a receptor involved in the regulation of the immune system. It is used to stimulate the immune system, and has potential application as an adjuvant therapy in cancer chemotherapy, although clinical trials have shown only modest benefits. It also worsens neuropathic pain in animal models and has been used to research the potential of targeting TLR8 in some kinds of chronic pain syndromes.
|
| Classification | Small molecule |
| Drug class | immunomodulators: immunomodulators, toll-like receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1 |
Identifiers
| PDB | — |
| CAS-ID | 926927-61-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301618 |
| ChEBI ID | — |
| PubChem CID | 16049404 |
| DrugBank | DB12303 |
| UNII ID | WP6PY72ZH3 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 270 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use